Neoscreen IRT
Accurate Neonatal Screening for Cystic Fibrosis Early detection of ...
Overview
Reliable Primary Test for CF Screening
Neoscreen IRT EIA is a solid-phase enzyme immunoassay designed for the quantitative determination of human immunoreactive trypsinogen (IRT) in dried blood spots. It enables large-scale neonatal screening, identifying elevated IRT levels to detect cystic fibrosis at the earliest stage.
Key Features
- Sensitive Detection : Quantifies human IRT accurately from dried blood disks.
- Solid-Phase Sandwich EIA : Uses a specific antibody-coated solid phase for IRT1, ensuring precise binding and measurement.
- Efficient Workflow : Excess conjugate and unbound hIRT are washed away before enzymatic reaction with TMB substrate.
- High Throughput : Suitable for large-scale neonatal screening programs.
- Clear Results : Chromogenic readout ensures easy interpretation of enzymatic activity.
- Validated for Clinical Use : Supports reliable early detection of cystic fibrosis in newborns.
Technical Specifications
- Sample Type : Dried blood spot on filter paper
- Analyte Measured : Human immunoreactive trypsinogen (IRT)
- Assay Type : Enzyme Immunoassay (EIA), solid phase
- Detection Method : Chromogenic substrate (TMB)
- Intended Use : Primary
Benefits
- Early identification of cystic fibrosis for timely intervention
- Supports large-scale newborn screening programs
- Reduces risk of delayed diagnosis of CF-related complications
- Reliable, reproducible, and clinically validated results
Inquiry Form